Skip to Content
Merck
All Photos(2)

Key Documents

SAB4200696

Sigma-Aldrich

Anti-Chondroitin Sulfate antibody, Mouse monoclonal

clone CS-56, purified from hybridoma cell culture

Synonym(s):

CSPG, chondroitin sulfate proteoglycan

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified from hybridoma cell culture
purified immunoglobulin

antibody product type

primary antibodies

clone

CS-56, monoclonal

form

buffered aqueous solution

species reactivity

mouse, chicken, bovine, human

packaging

antibody small pack of 25 μL

concentration

~1 mg/mL

technique(s)

immunofluorescence: 2.5-5 μg/mL using bovine BMGE cells
immunohistochemistry: 2.5-5 μg/mL using heat-retrieved formalin-fixed, paraffin-embedded human colon cancer sections and Biotin/ExtrAvidin ®-Peroxidase staining system.

isotype

IgM

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... CSPG4(1464)

General description

Monoclonal anti-chondroitin sulfate antibody, (mouse IgM isotype) is derived from the hybridoma CS56 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with Ventral membranes of chicken gizzard fibroblasts. This antibody recognizes chondroitin sulfate containing proteoglycans (CSPG) in bovine mammary gland epithelial (BMGE) cells and also in human, chicken and mouse fibroblasts or tissues.
Chondroitin sulfate proteoglycan 4 (CSPG4) or nerve/glial antigen 2 (NG2) is encoded by the gene mapped to human chromosome 15q24.2-15q24.3. It is a growth-inhibitory chondroitin sulfate proteoglycan (CSPG) produced after spinal cord injury. It has a single glycosaminoglycan (GAG) chain. The protein belongs to the transmembrane chondroitin sulfate proteoglycans family.

Immunogen

Ventral membranes of chicken gizzard fibroblasts

Biochem/physiol Actions

Chondroitin sulfate proteoglycan 4 (CSPG4) or nerve/glial antigen 2 (NG2) stimulates the activation of integrins in dorsal root ganglion neurons. It also has a role in stimulating inflammatory cytokine expression in microglia. CSPG4 plays a vital role in brain repair. Overexpression of the gene leads to developmental delay in patients with trisomy of 15q24-qter. CSPG4 serves as a potential prognostic biomarker and therapeutic target in malignant cancer.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

for continuous use, store at 2–8°C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation. Working dilution samples should be discarded if not used within 12 hours.

Other Notes

In order to obtain best results in different techniques and preparations we recommend determining optimal working concentration by titration test.

Legal Information

ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marian H Hettiaratchi et al.
Journal of controlled release : official journal of the Controlled Release Society, 297, 14-25 (2019-01-29)
Central nervous system (CNS) injuries, such as stroke and spinal cord injuries, result in the formation of a proteoglycan-rich glial scar, which acts as a barrier to axonal regrowth and limits the regenerative capacity of the CNS. Chondroitinase ABC (ChABC)
NG2/CSPG4 Proteoglycan as a Novel Prognostic Indicator and
Therapeutic Target in Malignant Cancer
Zhang H, et al.
Journal of stem cell research & therapy (2014)
Pure duplication of the distal long arm of chromosome 15 with ebstein anomaly and clavicular anomaly.
O'Connor R, et al.
Case Reports in Genetics (2011)
Amulya Sreekumar et al.
Cancer cell, 42(1), 52-69 (2023-12-09)
Breast cancer mortality results from incurable recurrences thought to be seeded by dormant, therapy-refractory residual tumor cells (RTCs). Understanding the mechanisms enabling RTC survival is therefore essential for improving patient outcomes. Here, we derive a dormancy-associated RTC signature that mirrors
Entrapment via synaptic-like connections between NG2 proteoglycan+ cells and dystrophic axons in the lesion plays a role in regeneration failure after spinal cord injury.
Filous AR, et al.
The Journal of Neuroscience, 34, 16369-16384 (2014)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service